Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Terminated 2Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Melanoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × 7-hydroxystaurosporine × Clear all
NCT00082017 2017-05-15

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
20 enrolled 13 charts
Lymphoid

Lymphoma, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT00072189 2015-03-02

A Phase II Study of UCN-01 in Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
17 enrolled 6 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡